KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study.

Geoffrey Liu, Benjamin J Solomon, Julien Mazieres, Dong-Wan Kim, Diego Cortinovis, Takako Inoue, Richu Sharma, Holger Thurm, Anna Polli, Todd M Bauer

Oncologist 30(10) oyaf287

PMID41124598
PMCIDPMC12557321
DOI10.1093/oncolo/oyaf287
发表日期2025-10-22
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:非 KM 图;Figure 1.:非 KM 图;Figure 2.:AI 判定为 other;Figure 3.:非 KM 图。
摘要

摘要

OBJECTIVE: With 5 years of follow-up in the phase 3 CROWN study, lorlatinib showed unprecedented improvement in progression-free survival coupled with prolonged intracranial efficacy in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC). Here, we report kinetics and mitigation practices of select adverse events (AEs) to inform therapy management strategies. DESIGN: Post hoc safety analyses from the CROWN study assessed the incidence, prevalence, time to onset, duration, management, and resolution of hyperlipidemia, edema, weight gain, central nervous system (CNS) AEs, and peripheral neuropathy in the lorlatinib group (n = 149). RESULTS: After 5 years of follow-up, no new safety signals were observed. All-cause any-grade and grade 3/4 AEs occurred in 100% and 77% of patients, respectively; AEs led to lorlatinib dose reduction in 23% of patients, dose interruption in 62%, and permanent discontinuation in 11%. The median time to onset of any-grade hyperlipidemia was 0.5 months; 71% of events were managed with lipid-lowering agents. Median time to onset of any-grade edema, weight gain, CNS AEs, and peripheral neuropathy ranged from 2 to 4 months. Most weight gain events (95%) were mitigated with lifestyle modifications. Incidence and prevalence of CNS AEs did not increase over time; 58% of events did not require medical intervention. CONCLUSIONS AND RELEVANCE: This post hoc analysis suggests that with longer lorlatinib exposure, no new safety signals emerged, and treatment discontinuation due to AEs remained low after 5 years of follow-up. Most AEs were effectively managed with dose modifications, indicating that current management strategies can be effective to mitigate toxicity. ClinicalTrials.gov NCT03052608.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical Abstract无图注
非 KM Figure
Figure 1.Summary of select adverse events. Abbreviation: CNS, central nervous system.
非 KM Figure
Figure 2.Median time to onset and median duration of select adverse events. Duration = AE end date/last visit date for ongoing AE − AE start date + 1 day. If a patient had multiple episodes of an AE, cumulative duration across all episodes was used adjusting for any overlap. Abbreviation: CNS, central nervous system.
非 KM Figure
Figure 3.Incidence and prevalence of (A) grade 2/3 weight gain and (B) CNS effects. Abbreviation: CNS, central nervous system.
非 KM Figure